IWO - iShares Russell 2000 Growth ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
194.80
-1.39 (-0.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close196.19
Open195.76
Bid0.00 x 0
Ask0.00 x 0
Day's Range194.37 - 196.50
52 Week Range160.19 - 201.80
Volume273,301
Avg. Volume552,092
Net Assets9.14B
NAV190.63
PE Ratio (TTM)N/A
Yield0.71%
YTD Return2.23%
Beta (3y)1.12
Expense Ratio (net)0.24%
Inception Date2000-07-24
Trade prices are not sourced from all markets
  • MiMedx Group on the Street: Analyst Recommendations in January
    Market Realist3 months ago

    MiMedx Group on the Street: Analyst Recommendations in January

    MiMedx Group (MDXG) operates in the regenerative biomaterials segment. MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.

  • An Insight into Cara Therapeutics’ Drug Pipeline
    Market Realist3 months ago

    An Insight into Cara Therapeutics’ Drug Pipeline

    Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.

  • Is US Job Market Getting Too Hot?
    Market Realist3 months ago

    Is US Job Market Getting Too Hot?

    ADP, a human capital management solution provider, releases a monthly report on US non-farm employment. This monthly report is prepared by using actual anonymous payroll data of 411,000 clients that ADP services. The report is released two days before the non-farm payrolls data, so this report prepares markets for any surprises in the jobs report.

  • Array BioPharma’s Financial Performance
    Market Realist3 months ago

    Array BioPharma’s Financial Performance

    What Led to Array BioPharma's Stellar Returns in Past 6 Months

  • Analysts’ Ratings for Radius Health and Its Peers in January
    Market Realist3 months ago

    Analysts’ Ratings for Radius Health and Its Peers in January

    Radius Health (RDUS) is a biopharmaceutical company that has recently turned into a commercial stage healthcare company. Of the seven analysts covering Radius Health in January 2018, three have given the stock “buy” or higher ratings, while four have given it “hold” ratings. The mean rating for the stock is 2.43, and it has a target price of $47.5.

  • Investopedia3 months ago

    Top 3 Small-Cap ETFs for 2018

    There's a case to be made that small-cap ETFs will outperform in the months ahead. Here are a few to consider.

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist3 months ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • What’s the Potential Market for Accelerate Diagnostics’ Products?
    Market Realist3 months ago

    What’s the Potential Market for Accelerate Diagnostics’ Products?

    How Is Accelerate Diagnostics Positioned at the Start of 2018? Accelerate Diagnostics’ (AXDX) Pheno System utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests (or AST), which determine if live bacterial or fungal cells are resistant or susceptible to a particular antimicrobial agent. The kit includes 140 assays for identification and susceptibility testing.

  • Market Realist4 months ago

    US Job Market Isn’t Showing Any Signs of Slowing Down

    As per the ADP National Employment Report, US private sector employment rose by 250,000 jobs in December, a healthy improvement from the 190,000 jobs added in November.

  • Investopedia5 months ago

    Top 3 Small-Cap ETFs for 2017

    There's a case to be made that small-cap ETFs will outperform in the final months of 2017. Here are a few to consider.

  • Dollar Rebounds: 5 ETFs to Cash in On
    Zacks6 months ago

    Dollar Rebounds: 5 ETFs to Cash in On

    Inside five ETFs that could rise in a rising dollar environment.

  • 6 ETFs Set to Win on Trump's Tax Reform
    Zacks7 months ago

    6 ETFs Set to Win on Trump's Tax Reform

    The legislative move has led to the return of Trump trade and investors are cashing in on the opportunity with ETFs that are deemed to gain most on tax reforms.

  • Market Realist7 months ago

    Why Robert Shiller Is Cautious about Equity Markets

    In a recent post by Project Syndicate, Nobel laureate and Yale economics professor Robert Shiller said that stock markets (SPY) are dangerously close to a bear market. Professor Shiller’s cyclically adjusted…...

  • Apple Leads Dow; FANG Gains Fade; Did Gold Flash A Buy Signal?
    Investor's Business Daily7 months ago

    Apple Leads Dow; FANG Gains Fade; Did Gold Flash A Buy Signal?

    Key U.S. stock indexes were slightly higher Tuesday as Apple rose but some other big-cap techs gave up early gains.

  • Apple, Techs Weigh On Stocks; Bitcoin Jumps; Time To Buy Gold?
    Investor's Business Daily7 months ago

    Apple, Techs Weigh On Stocks; Bitcoin Jumps; Time To Buy Gold?

    Key U.S. stock indexes were lower in the stock market today as Apple and other techs fell under pressure.

  • ETF Trends7 months ago

    Small-Cap ETFs for a More Risk-On Investor

    Small-capitalization stock investors were defensive going into the 2017, but they have quickly changed their tune, turning to more growth-weighted smaller company picks. Investors can also gain diversified ...

  • Market Realist7 months ago

    Sparsentan May Be Solid Near-Term Growth Driver for Ligand

    With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).

  • Market Realist8 months ago

    Technology Platforms and Research Programs Drive LGND’s Partnerships

    Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.

  • Bet on These ETFs on New Hopes for Tax Reform
    Zacks8 months ago

    Bet on These ETFs on New Hopes for Tax Reform

    President Donald Trump is expected to start a campaign for the highly anticipated tax reform next week.

  • Market Realist9 months ago

    Behind the Advisory Board’s Revenue Growth in 2017

    In 1Q17, the Advisory Board (ABCO) reported revenues of ~$194.1 million, which was higher than its guidance of $185 million–$190 million but ~0.7% lower YoY.

  • Zacks9 months ago

    Small Cap Growth ETF (IWO) Hits New 52-Week High

    This small cap growth ETF hits a new 52-week high. Are more gains in store for this ETF?

  • Market Realist9 months ago

    Flotek on the Street: The Latest Analyst Recommendations

    According to Reuters, on June 30, 2017, all of the sell-side analysts tracking Flotek Industries (FTK) have rated the stock a “buy” or some equivalent.

  • Which Of These June Winners Show Strength Amid Market Weakness?
    Investor's Business Daily10 months ago

    Which Of These June Winners Show Strength Amid Market Weakness?

    A large-cap blend ETF led U.S. diversified funds in June, but small-cap names dominated the rest of the list.